JP6457645B2 - ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤 - Google Patents

ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤 Download PDF

Info

Publication number
JP6457645B2
JP6457645B2 JP2017534297A JP2017534297A JP6457645B2 JP 6457645 B2 JP6457645 B2 JP 6457645B2 JP 2017534297 A JP2017534297 A JP 2017534297A JP 2017534297 A JP2017534297 A JP 2017534297A JP 6457645 B2 JP6457645 B2 JP 6457645B2
Authority
JP
Japan
Prior art keywords
gst
deoxy
sirna
nucleotide
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017534297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512110A (ja
JP2018512110A5 (OSRAM
Inventor
イン，ウェンビン
憲二郎 味呑
憲二郎 味呑
ハーボース，イェンス
博一 高橋
博一 高橋
絵里加 寺田
絵里加 寺田
ヂャン，ジュン
アーマディアン，モハンマド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of JP2018512110A publication Critical patent/JP2018512110A/ja
Publication of JP2018512110A5 publication Critical patent/JP2018512110A5/ja
Application granted granted Critical
Publication of JP6457645B2 publication Critical patent/JP6457645B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2017534297A 2014-12-26 2015-12-28 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤 Active JP6457645B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2014266198 2014-12-26
JP2014266198 2014-12-26
US201562184239P 2015-06-24 2015-06-24
US62/184,239 2015-06-24
US201562266664P 2015-12-13 2015-12-13
US62/266,664 2015-12-13
PCT/US2015/067553 WO2016106400A2 (en) 2014-12-26 2015-12-28 Rna interference agents for gst-pi gene modulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018134405A Division JP6600389B2 (ja) 2014-12-26 2018-07-17 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤

Publications (3)

Publication Number Publication Date
JP2018512110A JP2018512110A (ja) 2018-05-17
JP2018512110A5 JP2018512110A5 (OSRAM) 2018-08-30
JP6457645B2 true JP6457645B2 (ja) 2019-01-23

Family

ID=56151549

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2017534287A Pending JP2018513669A (ja) 2014-12-26 2015-12-28 Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤
JP2017534279A Active JP6865169B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ干渉剤
JP2017534297A Active JP6457645B2 (ja) 2014-12-26 2015-12-28 ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
JP2017534274A Pending JP2018513104A (ja) 2014-12-26 2015-12-28 Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法
JP2017534294A Active JP6730285B2 (ja) 2014-12-26 2015-12-28 Ｒｎａ干渉組成物及び悪性腫瘍のための方法
JP2017534275A Pending JP2018512373A (ja) 2014-12-26 2015-12-28 Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物
JP2017534286A Active JP6793649B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ剤
JP2021183788A Active JP7307137B2 (ja) 2014-12-26 2021-11-11 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2023106970A Active JP7655971B2 (ja) 2014-12-26 2023-06-29 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2025046972A Pending JP2025102833A (ja) 2014-12-26 2025-03-21 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017534287A Pending JP2018513669A (ja) 2014-12-26 2015-12-28 Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤
JP2017534279A Active JP6865169B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ干渉剤

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2017534274A Pending JP2018513104A (ja) 2014-12-26 2015-12-28 Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法
JP2017534294A Active JP6730285B2 (ja) 2014-12-26 2015-12-28 Ｒｎａ干渉組成物及び悪性腫瘍のための方法
JP2017534275A Pending JP2018512373A (ja) 2014-12-26 2015-12-28 Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物
JP2017534286A Active JP6793649B2 (ja) 2014-12-26 2015-12-28 Ｐ２１遺伝子調節のためのｒｎａ剤
JP2021183788A Active JP7307137B2 (ja) 2014-12-26 2021-11-11 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2023106970A Active JP7655971B2 (ja) 2014-12-26 2023-06-29 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP2025046972A Pending JP2025102833A (ja) 2014-12-26 2025-03-21 ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤

Country Status (10)

Country Link
US (14) US10264976B2 (OSRAM)
EP (9) EP3236976B1 (OSRAM)
JP (10) JP2018513669A (OSRAM)
KR (4) KR102527430B1 (OSRAM)
CN (7) CN108064155B (OSRAM)
AU (4) AU2015369595A1 (OSRAM)
BR (2) BR112017013597B1 (OSRAM)
CA (4) CA2971881C (OSRAM)
RU (4) RU2719185C2 (OSRAM)
WO (7) WO2016106402A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792299B2 (en) * 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
ES2789049T3 (es) * 2014-12-26 2020-10-23 Nitto Denko Corp Agentes de interferencia de ARN para modulación génica de GST-pi
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
EP3686184A3 (en) 2015-06-24 2020-08-26 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
KR102740699B1 (ko) 2015-12-13 2024-12-09 닛토덴코 가부시키가이샤 높은 활성 및 감소한 오프 타겟을 위한 sirna 구조
TWI780046B (zh) 2016-05-10 2022-10-11 國立大學法人東京醫科齒科大學 炎症促進因子表現抑制劑、其有效成分之篩選方法、對於該方法為有用之表現匣、診斷藥及診斷方法
JP2019508379A (ja) * 2017-02-16 2019-03-28 日東電工株式会社 悪性腫瘍に対する治療方法及び治療用組成物
CN111386105B (zh) * 2017-11-06 2023-09-15 日东电工株式会社 用于递送生物活性分子的膜融合化合物
SG11202004097RA (en) * 2017-11-09 2020-06-29 Univ Nat Corp Tokyo Medical & Dental Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method
CN109777798A (zh) * 2017-11-13 2019-05-21 深圳华大生命科学研究院 一种基于CRISPR技术治疗KRAS突变恶性肿瘤的sgRNA及其应用
JP6952594B2 (ja) * 2017-12-15 2021-10-20 洋司郎 新津 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
CN108486011B (zh) * 2018-03-27 2020-05-05 山东大学 一种三联苯化合物、制备方法及其应用
JP7432929B2 (ja) * 2018-05-31 2024-02-19 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途
WO2020009189A1 (ja) * 2018-07-05 2020-01-09 洋司郎 新津 Ｂｒａｆ阻害剤によるがん細胞の逆説的増殖を抑制する薬剤
CN112739382A (zh) * 2018-08-22 2021-04-30 日东电工株式会社 使用了hsp47的抑制物质的化疗剂敏感性的增强
EP3851125A4 (en) * 2018-08-22 2022-08-17 Nitto Denko Corporation AGENT WITH HSP47 INHIBITOR FOR SUPPRESSING METASTASIS
TWI840449B (zh) * 2018-11-16 2024-05-01 日商日東電工股份有限公司 用於惡性腫瘤之rna干擾輸送配方及方法
US20220016156A1 (en) * 2018-12-05 2022-01-20 Nitto Denko Corporation Rnai molecule for treating cancer
WO2020145350A1 (ja) 2019-01-10 2020-07-16 国立大学法人大阪大学 免疫賦活用組成物
CN113677373A (zh) * 2019-03-28 2021-11-19 日东电工株式会社 RNAi分子
JP2019116507A (ja) * 2019-04-25 2019-07-18 有限会社オービット Ｈｓｐ４７の発現促進剤、脱毛抑制方法、Ｈｓｐ４７の発現促進剤の製造方法及び飲食物の製造方法
WO2021001646A2 (en) * 2019-07-02 2021-01-07 Argonaute RNA Limited Apolipoprotein b antagonist
JP7692829B2 (ja) * 2019-07-30 2025-06-16 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
WO2021146548A1 (en) * 2020-01-17 2021-07-22 Anastasia Khvorova Universal dynamic pharmacokinetic-modifying anchors
CN112280800B (zh) * 2020-10-19 2022-06-07 上海市东方医院（同济大学附属东方医院） 一种构建体及其在制备动物衰老细胞示踪和衰老细胞清除药物中的应用
AU2021411103B2 (en) * 2020-12-28 2025-04-24 1E Therapeutics, Ltd. P21 mrna target areas for silencing
KR20230133859A (ko) 2020-12-28 2023-09-19 1이 테라퓨틱스 엘티디. p21 mRNA 표적화 DNA자임
KR102732913B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732909B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732912B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732910B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732911B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
WO2023210713A1 (ja) * 2022-04-27 2023-11-02 国立大学法人京都大学 心外膜細胞再生促進剤および心外膜細胞の再生促進方法
TW202529777A (zh) * 2023-09-28 2025-08-01 日商日東電工股份有限公司 組合療法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339303C (en) 1987-09-21 1997-08-19 Lyle John Arnold Jr. Non-nucleotide linking reagents for nucleotide probes
US5204241A (en) 1990-10-22 1993-04-20 Oxi-Gene Inc. Glutathione-S-transferase mu as a measure of drug resistance
US5786336A (en) 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
DE69431669T2 (de) 1993-09-02 2003-10-23 Ribozyme Pharmaceuticals, Inc. Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
DK0725788T3 (da) 1993-10-27 1999-08-23 Ribozyme Pharm Inc 2'-amido- og 2'-peptidomodificerede oligonukleotider
WO1996040205A1 (en) 1995-06-07 1996-12-19 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5968737A (en) 1996-11-12 1999-10-19 The University Of Mississippi Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
JPH10330249A (ja) * 1997-05-30 1998-12-15 Kureha Chem Ind Co Ltd レチノール化合物含有ｈｓｐ４７合成抑制剤
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
TW576838B (en) 1998-04-16 2004-02-21 Teijin Ltd Glutathione derivatives and application form thereof
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20070083945A1 (en) 2000-03-10 2007-04-12 Byrum Joseph R Nucleic acid molecules and other molecules associated with plants
US20030144236A1 (en) * 2000-03-29 2003-07-31 Weiss Robert H Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1)
WO2002010449A2 (en) 2000-07-28 2002-02-07 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
EP1627061B1 (en) 2001-05-18 2009-08-12 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
EP2213738B1 (en) * 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
AU2003297028A1 (en) 2002-12-13 2004-07-09 St. Jude Children's Research Hospital Glutathione-s-transferase test for susceptibility to parkinson's
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050142596A1 (en) 2003-11-14 2005-06-30 Krolewski Andrzej S. Methods of diagnosing renal and cardiovascular disease
WO2005089287A2 (en) 2004-03-15 2005-09-29 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
IL179285A (en) * 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
PL2386640T3 (pl) * 2004-08-26 2015-08-31 Engeneic Molecular Delivery Pty Ltd Dostarczanie funkcjonalnych kwasów nukleinowych do komórek ssaczych za pośrednictwem nienaruszonych minikomórek pochodzenia bakteryjnego
SI2730277T1 (sl) 2004-12-22 2020-07-31 Nitto Denko Corporation Nosilec zdravila in komplet za nosilec zdravila za zaviranje fibroze
US9393315B2 (en) * 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
JP2008536874A (ja) 2005-04-15 2008-09-11 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 中性脂質組成物によるｓｉＲＮＡの送達
WO2007072220A2 (en) * 2005-09-12 2007-06-28 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
ES2324128A1 (es) 2005-09-29 2009-07-30 Proyecto De Biomedicina Cima, S.L. Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares.
US20090220956A1 (en) 2005-10-25 2009-09-03 Dimitry Serge Antoine Nuyten Prediction of Local Recurrence of Breast Cancer
RU2448974C2 (ru) * 2005-11-01 2012-04-27 Элнилэм Фармасьютикалз, Инк. РНКи-ИНГИБИРОВАНИЕ РЕПЛИКАЦИИ ВИРУСА ГРИППА
CA2627585A1 (en) 2005-11-01 2007-05-10 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
DE602006005084D1 (de) 2005-11-17 2009-03-19 Childrens Medical Center Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen
US7729737B2 (en) 2005-11-22 2010-06-01 Isense Corporation Method and apparatus for background current arrangements for a biosensor
US8367628B2 (en) 2005-12-01 2013-02-05 Pronai Therapeutics, Inc. Amphoteric liposome formulation
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US9572886B2 (en) * 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US20070258952A1 (en) * 2006-05-04 2007-11-08 Baylor Research Institute Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
CN103614375A (zh) * 2006-05-11 2014-03-05 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
US8067390B2 (en) 2007-03-02 2011-11-29 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using siRNA in neutral liposomes
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
CN103215269B (zh) 2007-07-05 2015-01-21 诺瓦提斯公司 用于治疗病毒感染的dsRNA
CN105018492B (zh) 2007-08-27 2018-08-24 北京强新生物科技有限公司 不对称干扰rna的组合物及其用途
WO2009033284A1 (en) 2007-09-14 2009-03-19 Mcmaster University Inhibitors of collagen biosynthesis as anti-tumor agents
JP2011513342A (ja) * 2008-03-06 2011-04-28 ロッタファルム・ソシエタ・ペル・アチオニ 関節炎、癌および関連疼痛の治療のための２−アリールおよび２−ヘテロアリール４ｈ−１−ベンゾピラン−４−オン−６−アミジノ誘導体
JP2011528910A (ja) 2008-07-25 2011-12-01 アルニラム ファーマスーティカルズ インコーポレイテッド センス鎖中の一般塩基またはミスマッチを使用したｓｉＲＮＡサイレンシング活性の亢進
CN102159247A (zh) * 2008-07-30 2011-08-17 日东电工株式会社 药物载体
JP5823405B2 (ja) * 2009-11-04 2015-11-25 ザ ユニバーシティ オブ ブリティッシュ コロンビア 核酸含有脂質粒子および関連方法
TWI611021B (zh) * 2009-12-09 2018-01-11 日東電工股份有限公司 Ｈｓｐ４７表現之調節
EP2539469A4 (en) 2010-02-24 2013-07-31 Bodysync Inc METHOD FOR DETERMINING GENE NUTRITIONAL INTERACTIONS
WO2011112954A1 (en) * 2010-03-12 2011-09-15 The Wistar Institute Inhibition of p21 and use thereof for inducing tissue regeneration
US8372819B2 (en) 2010-04-11 2013-02-12 Salk Institute For Biological Studies Methods and compositions for targeting skip
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US20130052169A1 (en) 2010-05-06 2013-02-28 Stem Cell Medicine Ltd. Stem cell bank for personalized medicine
JP5950428B2 (ja) * 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
WO2012044620A2 (en) 2010-09-30 2012-04-05 Nitto Denko Corporation Modulation of timp1 and timp2 expression
US9339513B2 (en) * 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
US9011903B2 (en) * 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
EP2718261B1 (en) * 2011-06-08 2016-02-24 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing sirna activity
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
JP6023709B2 (ja) * 2011-06-21 2016-11-09 日東電工株式会社 アポトーシス誘導剤
CN102896619B (zh) * 2011-07-26 2015-04-22 苏州宝时得电动工具有限公司 动力工具及其操作方法
US20140351961A1 (en) * 2011-08-31 2014-11-27 Alexzander A. Asea Compositions and methods for treatment of metastatic cancer
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
EP2780455B1 (en) * 2011-11-17 2017-07-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Auto-recognizing therapeutic rna/dna chimeric nanoparticles (np)
AU2013262972A1 (en) * 2012-05-16 2014-12-11 Aadigen, Llc Multi-target modulation for treating fibrosis and inflammatory conditions
US20140134158A1 (en) 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
PT3489220T (pt) 2012-06-08 2021-10-22 Nitto Denko Corp Lípidos para formulações de administração de agentes terapêuticos
WO2013192364A1 (en) 2012-06-22 2013-12-27 The University Of Vermont And State Agricultural College Treatments of oxidative stress conditions
WO2014006020A1 (en) * 2012-07-02 2014-01-09 Fibrostatin, S.L. Gpbp-1 inhibition and its therapeutic use
US9708607B2 (en) 2012-08-03 2017-07-18 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
EA201891018A1 (ru) 2013-03-08 2018-09-28 Новартис Аг Липиды и липидные композиции для доставки активных агентов
CN103695421B (zh) * 2013-12-09 2016-06-15 浙江大学 一种特异抑制p21基因表达的siRNA及其应用
US10792299B2 (en) * 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
WO2016104588A1 (ja) * 2014-12-26 2016-06-30 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
KR102740699B1 (ko) * 2015-12-13 2024-12-09 닛토덴코 가부시키가이샤 높은 활성 및 감소한 오프 타겟을 위한 sirna 구조
JP6899201B2 (ja) 2016-06-23 2021-07-07 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物

Also Published As

Publication number Publication date
KR20170096199A (ko) 2017-08-23
JP2022036954A (ja) 2022-03-08
RU2719185C2 (ru) 2020-04-17
CA2972270A1 (en) 2016-06-30
CA2971881C (en) 2023-04-04
WO2016106405A1 (en) 2016-06-30
US20160186183A1 (en) 2016-06-30
JP7655971B2 (ja) 2025-04-02
CN107106591A (zh) 2017-08-29
WO2016106404A3 (en) 2016-09-15
EP3236975A2 (en) 2017-11-01
WO2016106406A2 (en) 2016-06-30
CN107106564A (zh) 2017-08-29
EP3240796A4 (en) 2018-08-08
RU2017126610A3 (OSRAM) 2019-07-17
JP2018512060A (ja) 2018-05-10
US20160208255A1 (en) 2016-07-21
WO2016106403A3 (en) 2016-08-18
JP6793649B2 (ja) 2020-12-02
JP6730285B2 (ja) 2020-07-29
EP3236974A2 (en) 2017-11-01
RU2017126613A (ru) 2019-01-28
CN107106591B (zh) 2020-09-01
EP3236945B1 (en) 2021-02-17
US20160215286A1 (en) 2016-07-28
US20160186182A1 (en) 2016-06-30
CN107106592B (zh) 2021-04-27
JP2025102833A (ja) 2025-07-08
CN108064155B (zh) 2021-06-08
RU2017126601A (ru) 2019-01-28
EP3236969A2 (en) 2017-11-01
JP2018513669A (ja) 2018-05-31
JP2018513668A (ja) 2018-05-31
US20160208265A1 (en) 2016-07-21
KR20170098929A (ko) 2017-08-30
EP3236976B1 (en) 2021-07-21
US20220087531A1 (en) 2022-03-24
AU2015369596A1 (en) 2017-07-27
USRE49431E1 (en) 2023-02-28
BR112017013597B1 (pt) 2024-01-16
CN108024961A (zh) 2018-05-11
EP3236976A4 (en) 2018-10-31
CN107108686B (zh) 2021-07-16
JP2018512110A (ja) 2018-05-17
RU2756253C2 (ru) 2021-09-28
CA2972268A1 (en) 2016-06-30
RU2017126613A3 (OSRAM) 2019-06-05
WO2016106401A2 (en) 2016-06-30
USRE48887E1 (en) 2022-01-11
CA2971881A1 (en) 2016-06-30
US10405749B2 (en) 2019-09-10
US20170298086A1 (en) 2017-10-19
AU2015369598A1 (en) 2017-07-27
EP3236973A2 (en) 2017-11-01
AU2015369592A1 (en) 2017-08-10
CA2972265A1 (en) 2016-06-30
EP3236973A4 (en) 2018-09-12
JP2018512041A (ja) 2018-05-10
WO2016106400A2 (en) 2016-06-30
US9695206B2 (en) 2017-07-04
AU2015369592B2 (en) 2021-05-06
EP3236974B1 (en) 2020-02-26
US20170218365A1 (en) 2017-08-03
EP3798308A1 (en) 2021-03-31
US20160208254A1 (en) 2016-07-21
USRE49229E1 (en) 2022-10-04
US20160376296A1 (en) 2016-12-29
US10047110B2 (en) 2018-08-14
WO2016106402A1 (en) 2016-06-30
WO2016106401A3 (en) 2016-09-15
RU2017126610A (ru) 2019-01-28
JP2018513104A (ja) 2018-05-24
EP3683309A1 (en) 2020-07-22
EP3236974B9 (en) 2020-08-05
RU2017126598A (ru) 2019-01-28
EP3236976A1 (en) 2017-11-01
AU2015369595A1 (en) 2017-07-27
US10264976B2 (en) 2019-04-23
EP3236975A4 (en) 2018-09-12
EP3240796B1 (en) 2020-12-16
JP6865169B2 (ja) 2021-04-28
JP7307137B2 (ja) 2023-07-11
US20160208256A1 (en) 2016-07-21
KR20170100010A (ko) 2017-09-01
WO2016106406A3 (en) 2016-11-03
US10047111B2 (en) 2018-08-14
JP2018512373A (ja) 2018-05-17
CN107108686A (zh) 2017-08-29
WO2016106404A2 (en) 2016-06-30
EP3236945A2 (en) 2017-11-01
BR112017013599A2 (pt) 2018-03-06
WO2016106400A3 (en) 2016-09-01
CN107106592A (zh) 2017-08-29
KR102527430B1 (ko) 2023-05-02
EP3236969A4 (en) 2018-06-13
EP3240796A1 (en) 2017-11-08
EP3236974A4 (en) 2018-06-13
BR112017013597A2 (pt) 2018-03-06
JP2023123743A (ja) 2023-09-05
US10023597B2 (en) 2018-07-17
CN108064155A (zh) 2018-05-22
CN108064153A (zh) 2018-05-22
EP3236945A4 (en) 2018-09-12
US9771582B2 (en) 2017-09-26
KR20170093988A (ko) 2017-08-16
WO2016106403A2 (en) 2016-06-30
US9580710B2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
JP7655971B2 (ja) ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤
JP6457704B2 (ja) 高活性及びオフターゲット削減のためのｓｉＲＮＡ構造
JP6600389B2 (ja) ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤
US11045488B2 (en) RNA interference agents for GST-π gene modulation
US20220047619A1 (en) Rna interference agents for gst-pi gene modulation
TWI715594B (zh) 用於麩胱甘肽Ｓ轉移酶Ｐｉ（ＧＳＴ－π）基因調控之ＲＮＡ干擾劑
HK1245674B (en) Rna interference agents for gst-pi gene modulation
HK1260156A1 (en) Sirna structures for high activity and reduced off target
HK1260156B (en) Sirna structures for high activity and reduced off target

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20171121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180717

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180801

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181220

R150 Certificate of patent or registration of utility model

Ref document number: 6457645

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250